In the first quarter of 2024, we delivered strong sales growth, driven by our growth platforms and new medicines. Find out more about Ipsen here: ipsen.com

Ipsen announces strong Q1 sales growth, Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms and new medicines, and confirms its full-year guidance. Find out more here: ipsen.com/press-releases…

Ipsen and Skyhawk Therapeutics announce global research collaboration focused on rare neurological diseases.

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases.
ipsen.com/press-releases…

Ipsen and Sutro announce global licensing agreement for pre-clinical ADC focused on solid tumors.

Ipsen and Sutro announce global licensing agreement for pre-clinical ADC focused on solid tumors.
ipsen.com/press-releases…

FDA approves Ipsen first line therapy in metastatic pancreatic adenocarcinoma (mPDAC), an advanced form of pancreatic cancer associated with a poor prognosis.

FDA approves Ipsen therapy as a first-line treatment for metastatic pancreatic adenocarcinoma, a challenging and complex form of advanced pancreatic cancer.
Learn more:ipsen.com/press-releases…

“As we report today on the solid full-year 2023 results, we’re also looking forward to a new era of dynamic growth. We’re anticipating four launches and further opportunities to enrich and advance our pipeline this year.” David Loew, CEO Ipsen
Learn more: ipsen.com/financial-resu…

We’ve posted solid FY 2023 results and are anticipating four launches in 2024. Learn more: ipsen.com/press-releases…

Ipsen announces presentation of new Phase III clinical trial data across tumor types at ASCO GU 2024 #GU24
Learn more: ipsen.com/press-releases…

FDA and EMA accept Ipsen’s regulatory submissions for a potential, novel second-line treatment for #PBC , a rare autoimmune cholestatic liver disease, which has seen no new treatments for nearly a decade.

Ipsen achieves simultaneous filing acceptances in the U.S., E.U. and UK for their novel investigational treatment for the rare autoimmune cholestatic liver disease, #PBC For more information: ipsen.com/press-releases…

At 2023 Capital Markets Day, Ipsen outlines next phase of growth and transformation and provides new mid-term outlook. ipsen.com/press-releases…

We are thrilled to announce our sponsorship of five incredibly talented athletes on their journeys to the 2024 Paralympic Games. Watch the full video here: lnkd.in/eRBjw_Tt

Exciting news from Ipsen's rare liver disease portfolio! 🚀 We're making great progress in developing a potential new treatment for primary biliary cholangitis (PBC). Stay tuned for updates.

The Dolon Report, published by EFPIA, explores the potential impact of the proposed European Pharmaceutical Legislation and the results aren’t promising for European health innovation. More information, including key stats from the report available here: shorturl.at/jkmBD

We are delighted to have been named one of the world’s best employers 🌟 by Forbes magazine in 2023. 🎉 Bravo to our teams for making Ipsen a truly outstanding workplace! 👏ipsen.com/general/ipsen-…

Ipsen was officially recognized by Great Place to Work in an additional 14 countries. We are now accredited by external organizations in 25 countries. This means the world to us and encourages us in our journey to build a positive workplace for all!
shorturl.at/mvHO9

We’re pleased to announce solid results in the first nine months of 2023 as we continue to deliver innovative treatments to people living with high unmet medical needs.